Table 1.
Summary of the research focused on understanding the impact of BECs on ASMCs.
Outcome | Model | Animals | Cell type | Stressor | Means of interaction | Mechanism | Reference |
---|---|---|---|---|---|---|---|
Relaxation | In vitro | Human Guinea Pig | BEC | None | GABA | Unknown | [59] |
In vitro | Human | BEAS-2B ASMC |
None | Acetylcholine Nitric oxide |
Unknown | [64] | |
In vitro | Human | ASMC BEAS-2B BEC |
None | ASMCs COX-1 Prostaglandin E receptors 2 and 4 |
Unknown | [67] | |
Contraction | In vitro | Human | ASMC BEC |
Mechanical pressure | Endothelin-1 | Unknown | [68] |
Ex vivo/In vitro | Rat Human |
BEC | Physical injury | Unknown soluble mediators | Unknown | [69] | |
Ex vivo/In vitro | Human | ASMC | Rhinovirus | IP-10 MIP-1b |
Unknown | [75] | |
In vivo | Mouse | NA | IL-13 | Unknown | Unknown | [76] | |
In vivo/In vitro | Mouse Human |
BEC | IL-13 | CCL2/CCL24 CXCL1 |
Β-arrestin pathway | [77] | |
In vivo/Ex vivo | Mouse Human |
NA | Genetic | Neuropeptide Y | Unknown | [55] | |
Migration | In vitro | Human | BEAS-2B BEC ASMC |
YKL-40 | IL-8 | Activating MAPK and NF-κB Pathways | [81] |
In vitro | Human | ASMC BEC BEAS-2B |
TNFα | IL-8 RANTES |
Unknown | [79] | |
In vitro | Human | ASMC BEC |
TNFα | IL-8 CCL5 |
Unknown | [104] | |
In vitro | Human | ASMC A549 |
CSE | IL-8 TGF-β1 |
M3 mAChR | [92] | |
In vitro | Human | ASMC BEAS-2B HBE135 |
Nonylphenol | IL-6/IL-8 | Unknown | [93] | |
In vitro | Human | ASMC BEC |
Rhinovirus | CXCL8 CCL5 |
Unknown | [94] | |
In vitro | Human | ASMC BEC |
Rhinovirus | CXCL10 | Unknown | [95] | |
Proliferation | In vitro | Human | ASMC BEC BEAS-2B |
None | ASMCs COX-1 Prostaglandin E receptors 2 and 4 |
Unknown | [67] |
In vitro/In vivo | Human Rabbit |
ASMC BEC |
Physical injury | IL-6/IL-8 MCP-1 MMP-9 |
Unknown | [54] | |
In vitro | Human | ASMC BEC |
Mechanical pressure | Endothelin-1 | Unknown | [68] | |
In vitro | Human | BEAS-2B BEC ASMC |
YKL-40 | IL-8 | Activating MAPK and NF-κB Pathways | [81] | |
In vitro | Human | ASMC BEC |
Amphiregulin | Unknown | COX-2 activity in BEC | [8] | |
In vitro | Human | ASMC 293LT1 A549 BEC |
Leukotriene D4 LTD4 | TGF-B1 | CysLT1 receptor | [100] | |
In vitro/Ex vivo | Human | ASMC BEC |
HDM | Leukotriene C4 | PAR-2 receptor | [103] | |
In vitro | Human | ASMC BEAS-2B HBE135 |
Nonylphenol | IL-6/IL-8 | Unknown | [93] |
* BEC: Primary bronchial epithelial cell, ASMC: Primary airway smooth muscle cell, NA: Non-applicable.